Yoichi Furukawa Selected Research

TCF Transcription Factors

3/2020	Discovery of chemical probes that suppress Wnt/β-catenin signaling through high-throughput screening.
2/2004	Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells.
10/2003	Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex.
10/2002	Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoichi Furukawa Research Topics

Disease

48	Neoplasms (Cancer) 03/2021 - 01/2002
22	Colorectal Neoplasms (Colorectal Cancer) 08/2022 - 03/2002
20	Carcinogenesis 01/2021 - 08/2002
12	Colonic Neoplasms (Colon Cancer) 04/2017 - 03/2002
10	Hepatocellular Carcinoma (Hepatoma) 08/2010 - 06/2002
7	Breast Neoplasms (Breast Cancer) 10/2019 - 02/2006
6	Stomach Neoplasms (Stomach Cancer) 01/2020 - 12/2002
4	Adenocarcinoma 03/2021 - 06/2002
4	Cholangiocarcinoma 03/2008 - 06/2005
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 03/2004
3	Carcinoma (Carcinomatosis) 09/2005 - 08/2002
2	Infections 01/2022 - 10/2006
2	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 12/2016 - 12/2012
2	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2015 - 02/2004
2	Neoplasm Metastasis (Metastasis) 02/2010 - 02/2004
2	Testicular Neoplasms (Testicular Cancer) 08/2005 - 08/2004
2	Adenoma (Adenomas) 02/2004 - 06/2002
1	Primary Myelofibrosis (Myelosclerosis) 01/2022
1	Microsatellite Instability 03/2021
1	Bacteremia 01/2021
1	HIV Infections (HIV Infection) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Dysbiosis 01/2021
1	Clostridium Infections 01/2021
1	Glucose Metabolism Disorders 01/2021
1	Inflammation (Inflammations) 01/2021
1	Disease Progression 01/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2020
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2020
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2020
1	Neutropenia 01/2019

Drug/Important Bio-Agent (IBA)

30	Complementary DNA (cDNA)IBA 09/2010 - 01/2002
22	Proteins (Proteins, Gene)FDA Link 03/2021 - 06/2003
9	Small Interfering RNA (siRNA)IBA 01/2020 - 05/2004
8	Pharmaceutical PreparationsIBA 01/2021 - 01/2002
6	CateninsIBA 08/2022 - 01/2014
6	AntigensIBA 09/2010 - 08/2004
5	beta CateninIBA 12/2005 - 08/2002
4	Histones (Histone)IBA 01/2022 - 10/2005
4	Bevacizumab (Avastin)FDA Link 01/2021 - 10/2016
4	TCF Transcription FactorsIBA 03/2020 - 10/2002
4	Biological ProductsIBA 08/2014 - 11/2004
4	Peptides (Polypeptides)IBA 09/2010 - 12/2004
4	Tumor Biomarkers (Tumor Markers)IBA 06/2005 - 06/2003
3	Estrogen ReceptorsIBA 10/2019 - 10/2014
3	Aromatase InhibitorsIBA 10/2019 - 10/2014
3	MutL Protein Homolog 1IBA 08/2019 - 12/2012
3	HLA-A24 AntigenIBA 09/2010 - 10/2004
3	Histone MethyltransferasesIBA 11/2007 - 08/2004
3	HLA-A*02:01 antigenIBA 05/2006 - 12/2004
3	Calcibiotic Root Canal SealerIBA 11/2004 - 02/2004
3	OligonucleotidesIBA 01/2004 - 06/2002
2	Lysine (L-Lysine)FDA Link 01/2022 - 01/2011
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 04/2003
2	CytokinesIBA 01/2021 - 08/2010
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 02/2010
2	N- (3- phenyl- n- propyl)- 1- phenyl- 2- aminopropane (PPAP)IBA 01/2020 - 08/2019
2	InterferonsIBA 01/2019 - 11/2017
2	Gemcitabine FDA Link 01/2019 - 04/2003
2	LigandsIBA 11/2018 - 07/2009
2	Estrogens (Estrogen)FDA Link 12/2016 - 10/2014
2	DNA (Deoxyribonucleic Acid)IBA 12/2016 - 12/2015
2	Docetaxel (Taxotere)FDA Link 10/2016 - 04/2003
2	Biomarkers (Surrogate Marker)IBA 08/2011 - 08/2010
2	MethyltransferasesIBA 01/2011 - 02/2006
2	GlypicansIBA 12/2004 - 06/2003
2	Neoplasm Antigens (Tumor Antigens)IBA 12/2004 - 10/2004
2	EpitopesIBA 12/2004 - 12/2004
1	ChromatinIBA 01/2022
1	Polycomb Repressive Complex 2IBA 01/2022
1	Surface-Active Agents (Surfactants)IBA 03/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	AutoantibodiesIBA 01/2021
1	immune RNA (I-RNA)IBA 01/2021
1	alpha-hydroxyglutarateIBA 01/2021
1	Toll-Like Receptor 7IBA 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021
1	Cetuximab (Erbitux)FDA Link 01/2021
1	LuciferasesIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	TubulinIBA 12/2020
1	PTC596IBA 12/2020
1	Tubulin ModulatorsIBA 12/2020
1	PTC-028IBA 12/2020
1	Exosome Multienzyme Ribonuclease ComplexIBA 01/2020
1	hydrogen sulfite (bisulfite)IBA 08/2019
1	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 08/2019
1	5-Methylcytosine (5 Methylcytosine)IBA 08/2019
1	ErbB Receptors (EGF Receptor)IBA 12/2018
1	Selective Estrogen Receptor Modulators (SERM)IBA 12/2018

Therapy/Procedure

7	Immunotherapy 09/2010 - 08/2004
6	Therapeutics 03/2021 - 04/2016
6	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
6	Lasers (Laser) 06/2005 - 06/2002
1	Ligation 11/2021
1	Art Therapy 01/2021
1	Fecal Microbiota Transplantation 01/2021
1	Phage Therapy 01/2020